In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alpha hydroxy acids consumer education, label warnings under consideration by FDA.

This article was originally published in The Rose Sheet

Executive Summary

FDA CONSIDERING AHA CONSUMER EDUCATION PROGRAM, WARNING LABEL REQUIREMENTS as part of its safety determination for the lactic acid and glycolic acid families, FDA Office of Cosmetics and Colors Director John Bailey, MD, told the Cosmetics Ingredient Review Expert Panel at its June 6 meeting in Washington, D.C. Bailey noted the agency is considering these requirements while it works with the National Toxicology Program to conduct toxicological studies and gather safety data on alpha hydroxy acids.

You may also be interested in...



CIR Panel To Consider Re-Reviewing AHA Safety As Use Rises

With use of alpha hydroxy acids in personal-care products on the upswing, the Cosmetic Ingredient Review Expert Panel will revisit the ingredient group’s safety report and consider re-opening a review at its next meeting.

Interim AHA Labeling Guidance Proposed By FDA Pending NTP Study Results

FDA's draft guidance for labeling of alpha hydroxy acid-containing products is an interim step taken while the agency continues to evaluate AHAs and their impact on increased skin sensitivity to the sun, FDA says in a Dec. 2 1Federal Register notice

Interim AHA Labeling Guidance Proposed By FDA Pending NTP Study Results

FDA's draft guidance for labeling of alpha hydroxy acid-containing products is an interim step taken while the agency continues to evaluate AHAs and their impact on increased skin sensitivity to the sun, FDA says in a Dec. 2 1Federal Register notice

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel